Better Buy: Moderna vs. Biocryst Pharmaceuticals [The Motley Fool]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: The Motley Fool
Most stocks have performed dismally so far in 00 due to the COVID-9 outbreak. But biotech stocks, in general, have fared pretty well. Some have even delivered exceptional returns in recent months.Moderna(NASDAQ:MRNABiocryst PharmaceuticalsNASDAQ:BCRX 00 indexWhich of these two biotech stocks is the better pick for investors going forward? Here's how Moderna and Biocryst compare.Image source: Getty Images.The case for ModernaIf you handicap the race for developing a novelcoronavirusTechnically, though, it wasn't Moderna conducting this study. The National Institutes of Health (NIH) is running the clinical trial evaluating mRNA-7. The NIH's National Institute of Allergy and Infectious Diseases (NIAID) even collaborated with Moderna in designing the vaccine. This close relationship with the NIH gives Moderna increased credibility in the eyes of many investors.But whilea lot of people are talking about ModernaModerna also has a couple of other phase programs, both of which involve big pa
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna (NASDAQ:MRNA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Moderna (NASDAQ:MRNA) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Moderna (NASDAQ:MRNA) was given a new $18.00 price target on by analysts at UBS Group AG.MarketBeat
- Moderna (NASDAQ:MRNA) had its price target raised by analysts at Leerink Partners from $15.00 to $18.00. They now have an "underperform" rating on the stock.MarketBeat
- Moderna (NASDAQ:MRNA) had its price target lowered by analysts at Royal Bank Of Canada from $28.00 to $25.00. They now have a "sector perform" rating on the stock.MarketBeat
MRNA
Earnings
- 11/6/25 - Beat
MRNA
Sec Filings
- 12/2/25 - Form 4
- 12/2/25 - Form 4
- 12/1/25 - Form 4
- MRNA's page on the SEC website